Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00858871 · ClinicalTrials.gov registry record · Phase 3
First Line Hepato Cellular Carcinoma (HCC)
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,714
- Enrollment target
NCT00858871 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,714 participants.
The verdict
NCT00858871, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,714 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
Interventions
- DRUG Placebo
- DRUG Sorafenib
- DRUG Brivanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,714 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00858871
The ClinicalTrials.gov registry entry for NCT00858871 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,714 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00858871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00858871 about?
NCT00858871 is a clinical study titled "First Line Hepato Cellular Carcinoma (HCC)". The purpose of this study is to compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic therapy.
What is the current status of trial NCT00858871?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,714 participants. The study started on 2009-05. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00858871?
The interventions under investigation include: Placebo (DRUG), Sorafenib (DRUG), Brivanib (DRUG).
Who is sponsoring clinical trial NCT00858871?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.